Until around 15 years ago, the forecast for spending included nominal annual growth rates of 5-10 per cent, but it was not real. It was not linked to anything. It could not be used to offset new listings because of Budget rules, which remain in place today, and it just made the program a target. It reflects a long-term, enduring dynamic. Nothing will change in the absence of reforming the system's basic architecture.
They used to forecast growth, it was not real and couldn't be used, and it made the program a target for cuts
May 21, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The private market might do what two decades of PBS reform attempts couldn't
October 12, 2026 - - Latest News -
The full set of numbers tell the story and reveal the massive funding shortfall
October 12, 2026 - - Latest News -
Private prescription market heads towards $4 billion as PBS spending stalls
October 12, 2026 - - Latest News -
The 'Dispatched' Podcast Week in Review - Series 5. Ep.35
October 9, 2026 - - Podcast -
PhRMA goes to court over price rule that uses Australia as a benchmark
October 9, 2026 - - Latest News -
A tale of two systems with billions shifting to the private market
October 9, 2026 - - Latest News -
GLP-1s are quickly reshaping the Australian prescription medicines market
October 9, 2026 - - Latest News
